Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ACADIA Pharmaceuticals Inc

+ Add to Watchlist


32.0400 USD 0.5500 1.69%

As of 20:10:00 ET on 04/01/2015.

Snapshot for ACADIA Pharmaceuticals Inc (ACAD)

Open: 32.5300 Day's Range: 31.1640 - 32.6800 Volume: 1,727,103
Previous Close: 32.5900 52wk Range: 15.6400 - 46.4800 1-Yr Rtn: +31.42%

Stock Chart for ACAD

No chart data available.
  • ACAD:US 32.0400
  • 1D
  • 1M
  • 1Y
Interactive ACAD Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ACAD

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.9400
Est. EPS (USD) (12/2015) -0.9880
Est. PEG Ratio -
Market Cap (M USD) 3,209.50
Shares Outstanding (M) 100.17
30 Day Average Volume 2,830,640
Price/Book (mrq) 10.3574
Price/Sale (ttm) 26,115.7209
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ACAD

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ACAD

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

Stephen R Davis "Steve"Interim CEO/Exec VP/CFOTerrence O MooreExec VP/Chief Commercial Officer
Roger M MillsExec VP:Dev/Chief Medical OfcrGlenn F BaityVP/Secy/General Counsel
More Company Profile & Key Executives for ACAD

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil